Physiomics Plc Cash Flow Conversion Efficiency

Latest as of December 2025: -0.514x

Physiomics Plc cash flow conversion efficiency. Based on the latest financial reports, Physiomics Plc (PYC) has a cash flow conversion efficiency ratio of -0.514x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-202.00K ≈ $-24.58 USD) by net assets (GBX393.00K ≈ $47.82 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Physiomics Plc (2001–2025)

Cash flow conversion efficiency of Physiomics Plc from 2001 to 2025. This chart illustrates how Physiomics Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Physiomics Plc (PYC) stock price for real-time trading data and today's change.

Physiomics Plc Cash Flow Conversion Ratio Explained

Physiomics Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Physiomics Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Physiomics Plc ranked by their cash flow conversion efficiency. Also see PYC stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Selcuk Gida Endustri Ihracat Ithalat AS
IS:SELGD
0.021x
Marwyn Value Investors Ltd
LSE:MVIR
0.020x
British and American Investment Trust PLC
LSE:BAF
-0.128x
IQ-AI Ltd
LSE:IQAI
-0.220x
Platinum Industries Ltd
NSE:PLATIND
-0.017x
Cincon Electronics Co Ltd
TWO:3332
0.024x
Coral Products
LSE:CRU
-0.072x
Premier African Minerals Ltd
LSE:PREM
-2.033x

Annual Cash Flow Conversion Efficiency for Physiomics Plc (2001–2025)

The table below shows the annual cash flow conversion efficiency of Physiomics Plc from 2001 to 2025. Review PYC free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 GBX692.17K
≈ $84.22
GBX-546.14K
≈ $-66.45
-0.789x +59.33%
2024-06-30 GBX282.53K
≈ $34.38
GBX-548.13K
≈ $-66.69
-1.940x -289.48%
2023-06-30 GBX531.72K
≈ $64.69
GBX-264.86K
≈ $-32.23
-0.498x -39.03%
2022-06-30 GBX974.81K
≈ $118.61
GBX-349.25K
≈ $-42.49
-0.358x -1185.23%
2021-06-30 GBX1.17 Million
≈ $141.83
GBX-32.50K
≈ $-3.95
-0.028x +68.31%
2020-06-30 GBX1.31 Million
≈ $160.00
GBX-115.69K
≈ $-14.08
-0.088x +62.80%
2019-06-30 GBX607.91K
≈ $73.97
GBX-143.77K
≈ $-17.49
-0.237x +3.89%
2018-06-30 GBX690.03K
≈ $83.96
GBX-169.80K
≈ $-20.66
-0.246x +81.53%
2017-06-30 GBX328.25K
≈ $39.94
GBX-437.27K
≈ $-53.20
-1.332x +21.60%
2016-06-30 GBX204.15K
≈ $24.84
GBX-346.87K
≈ $-42.20
-1.699x -40.90%
2015-06-30 GBX325.62K
≈ $39.62
GBX-392.65K
≈ $-47.77
-1.206x +53.18%
2014-06-30 GBX136.49K
≈ $16.61
GBX-351.51K
≈ $-42.77
-2.575x -25.62%
2013-06-30 GBX255.82K
≈ $31.13
GBX-524.49K
≈ $-63.81
-2.050x -172.94%
2012-06-30 GBX734.57K
≈ $89.38
GBX-551.77K
≈ $-67.13
-0.751x +11.68%
2011-06-30 GBX756.00K
≈ $91.98
GBX-643.00K
≈ $-78.23
-0.851x -54.23%
2010-06-30 GBX787.00K
≈ $95.76
GBX-434.00K
≈ $-52.81
-0.551x -80.29%
2009-06-30 GBX-85.00K
≈ $-10.34
GBX26.00K
≈ $3.16
-0.306x -188.03%
2008-06-30 GBX-354.00K
≈ $-43.07
GBX-123.00K
≈ $-14.97
0.347x +108.89%
2007-06-30 GBX99.00K
≈ $12.05
GBX-387.00K
≈ $-47.09
-3.909x -194.51%
2006-06-30 GBX-66.00K
≈ $-8.03
GBX-273.00K
≈ $-33.22
4.136x +499.14%
2005-06-30 GBX413.00K
≈ $50.25
GBX-428.00K
≈ $-52.08
-1.036x -268.28%
2004-06-30 GBX-354.00K
≈ $-43.07
GBX-218.00K
≈ $-26.52
0.616x -60.87%
2003-06-30 GBX-129.00K
≈ $-15.70
GBX-203.00K
≈ $-24.70
1.574x +233.71%
2001-06-30 GBX130.00K
≈ $15.82
GBX-153.00K
≈ $-18.62
-1.177x --

About Physiomics Plc

LSE:PYC UK Biotechnology
Market Cap
$23.44K
GBX192.61 Million GBX
Market Cap Rank
#31775 Global
#1250 in UK
Share Price
GBX0.43
Change (1 day)
+0.00%
52-Week Range
GBX0.27 - GBX0.70
All Time High
GBX17.13
About

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more